Greenwich, Connecticut, August 3, 2026
Ceruvia Lifesciences announced an $8 million investment to advance the clinical development of BOL-148, its proprietary non-hallucinogenic LSD analog being developed as a potential treatment for cluster headache. The founder-backed investment will fully fund the next stage of the program, including an integrated Phase 1/2 clinical study designed to transition efficiently from dose escalation in healthy volunteers to proof-of-concept evaluation in patients with cluster headache. The financing represents an important clinical development milestone for Ceruvia as it works to assess the safety, efficacy, dose response and durability of effect of its investigational neurological therapy.
Integrated Phase 1/2 Trial Advances BOL-148 Development
The planned clinical study will consist of two parts designed to generate safety and proof-of-concept evidence within a single development program. Part 1 will be a standard Phase 1 single ascending dose study in healthy adults, evaluating the candidate as Ceruvia establishes its clinical profile across increasing dose levels. Following the Phase 1 portion, the program is expected to advance into Part 2, a randomized, placebo-controlled Phase 2 study in patients with cluster headache. The Phase 2 component is designed to evaluate the safety and efficacy of BOL-148 in the target patient population while also investigating dose response and durability of therapeutic effect. Ceruvia expects to submit a Clinical Trial Application in Germany in September 2026, with first participant enrollment anticipated during the fourth quarter of 2026. Top-line data from the Phase 1 portion are expected during the second quarter of 2027, after which the program is planned to progress into Phase 2 proof-of-concept evaluation. Results from the integrated trial are intended to inform the design and execution of a future Phase 3 pivotal study in the United States and European Union.
Non-Hallucinogenic LSD Analog Targets Cluster Headache
NYPRG-101, also known as BOL-148, is Ceruvia’s proprietary non-hallucinogenic LSD analog being developed specifically as a potential therapy for cluster headache. According to Ceruvia, the program builds on encouraging preliminary clinical observations from an earlier Harvard Medical School trial in which patients with chronic cluster headache achieved complete and durable responses, as well as Ceruvia’s own Phase 1 safety experience in healthy volunteers. The company believes BOL-148 could potentially provide a differentiated treatment approach capable of producing durable remission following a short course of therapy. However, the candidate remains investigational, and the planned Phase 1/2 program will be important for establishing its clinical safety and therapeutic potential. Cluster headache is considered one of the most severe neurological pain disorders, characterized by episodes of extreme pain. Treatment options remain limited, particularly for chronic cluster headache, where Ceruvia notes that there are currently no FDA-approved preventive therapies. This unmet need is central to the company’s clinical development strategy for BOL-148.
Advertisement
$8 Million Investment Supports Path Toward Phase 3
The $8 million financing fully funds Ceruvia’s planned integrated Phase 1/2 program, allowing the company to advance BOL-148 through the next major stages of clinical development. By combining healthy-volunteer dose escalation and patient proof-of-concept evaluation within an integrated study, Ceruvia aims to efficiently generate the clinical evidence required to guide later-stage development. The program also reflects the company’s broader focus on developing neurotransformational medicines for underserved neurological and psychiatric disorders. Founded in 2017, Ceruvia is a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat headache disorders, obsessive-compulsive disorder and substance use disorders. The company has a history of research collaborations with investigators at Yale University School of Medicine, NYU School of Medicine and Harvard Medical School. With the new financing secured, the upcoming BOL-148 Phase 1/2 clinical trial will represent a critical test of whether the non-hallucinogenic LSD analog can demonstrate a favorable safety profile and meaningful therapeutic activity in patients with cluster headache. Successful results could establish the foundation for a Phase 3 registration program across the U.S. and Europe, advancing Ceruvia’s goal of developing a new treatment option for patients affected by this severe neurological condition.
Source: Ceruvia Lifesciences press release
